April 2025

• The  Japanese Clinical Trials Registry was updated to a new link https://rctportal.mhlw.go.jp/en/

• All links were checked and working appropriately

• Clinical trial numbers were updated accordingly

  • Cytarabine: US clinical trials from 409 to 405, European clinical trials from 88 to 70 

  • Vidarabine: US clinical trials from 23 to 21

  • Ziconotide: US clinical trials from 3 to 2

  • Omega-3-acid ethyl ester: US clinical trials from 19 to 16, European clinical trials from 1 to 0

  • Eicosapentaenoic acid ethyl esters: US clinical trials from 6 to 5

  • Eribulin mesylate: European clinical trials from 15 to 14, Chinese clinical trials from 16 to 17

  • Brentuximab vedotin: European clinical trials from 30 to 22

  • Trabectedin: US clinical trials from 22 to 19, Japanese clinical trials from 0 to 2, European clinical trials from 9 to 6

  • Plitidepsin: US clinical trials from 0 to 1

  • Polatuzumab vedotin: US clinical trials from 56 to 55, European clinical trails from 10 to 9

  • Enfortumab vedotin-ejfv: US clinical trials from 42 to 49, European clinical trials from 8 to 7, Japanese clinical trials from 11 to 9

  • Lurbinectedin: US clinical trials from 28 to 27, Japanese clinical trials from 2 to 1

  • Disitamab vedotin: US clinical trials from 82 to 84, Japanese clinical trials from 1 to 0, Chinese clinical trials from 26 to 33

  • Tisotumab vedotin: Japanesse clinical trials from 0 to 2
     

January 2025

• All links were checked and working appropriately

• Clinical trial numbers were updated accordingly

  • Cytarabine: US clinical trials from 405 to 409, European clinical trials from 115 to 88 , and Chinese clinical trials from 63 to 68

  • Vidarabine: Link to company/institution changed: https://lgmpharma.com/product/vidarabine/

  • Omega-3-acid ethyl ester: US clinical trials from 20 to 19

  • Eicosapentaenoic acid ethyl esters: US clinical trials from 4-6

  • Eribulin mesylate: US clinical trials from 70 to 78, European clinical trials from 20 to 15 Chinese clinical trials from 15 to 16

  • Brentuximab vedotin: US clinical trials from 70 to 68, European clinical trials from 39 to 30

  • Trabectedin: US clinical trials from 22 to 19, European clinical trials from 19 to 9

  • Plitidepsin: European clinical trials from 3 to 2

  • Polatuzumab vedotin: US clinical trials from 51 to 56, European clinical trails from 11 to 10, Chinese clinical trials from 2 to 6

  • Enfortumab vedotin-ejfv: US clinical trials from 39 to 42, European clinical trials from 9 to 8, Japanese clinical trials from 13 to 11

  • Lurbinectedin: European Clinical Trials from 4 to 3

  • Disitamab vedotin: US clinical trials from 78 to 82
     

October 2024

• All links were checked and working appropriately

• Clinical trial numbers were updated accordingly

  • Cytarabine: US clinical trials from 410 to 405, European clinical trials from 119 to 115, Japanese clinical trials from 20 to 22, and Chinese clinical trials from 60 to 63

  • Ziconotide: US clinical trials from 2 to 3

  • Omega-3-acid ethyl ester: US clinical trials from 21 to 20

  • Eribulin mesylate: US clinical trials from 73 to 70, European clinical trials from 21 to 20

  • Brentuximab vedotin: US clinical trials from 72 to 70

  • Trabectedin: US clinical trials from 21 to 22, European clinical trials from 20 to 18

  • Polatuzumab vedotin: US clinical trials from 48 to 51

  • Enfortumab vedotin-ejfv: US clinical trials from 37 to 39, Japanese clinical trials from 12 to 13

  • Lurbinectedin: US clinical trials from 29 to 28, European clinical trials from 5 to 4, Japanese clinical trials from 3 to 2, Chinese clinical trials from 0 to 1

  • Disitamab vedotin: US clinical trials from 77 to 78, Chinese clinical trials from 24 to 26

• Withdrawn

  • Panobinostat: European clinical trials from 5 to 4

  • Belantamab Mafodotin-blmf: European clinical trials from 17 to 14, Japanese clinical trials from 3 to 2
     

August 2024 

• All links were checked and are working appropriately. 
  NOTE: Clinical trial numbers were updated and may include Phase 3, as well as Phase 2 and Phase 1 if ongoing.  
  o    Cytarabine: US clinical trials from 411 to 410, European clinical trials from 120 to 119, Japanese clinical trials from from 21 to 20, Chinese clinical trials from 57 to 60
  o    Eribulin Mesylate: US clinical trials from 79 to 73, Japanese clinical trials from 6 to 5
  o     Brentuximab vedotin:  US active clinical trials dropped from 73 to 72, Japanese clinical trials from 1 to 2, Chinese clinical trials 1 to 2 
  o    Trabectedin: US clinical trials from 22 to 21
  o    Polatuzumab vedotin:  US clinical trials from 45 to 48, European clinical trials from 12 to 11, Japanese clinical trials from 6 to 4.
  o    Enfortumab vedotin-ejfv: US clinical trials from 34 to 37, European clinical trials from 5 to 4.
  o    Lurbinectedin: US clinical trials from 28 to 29, European clinical trials from 5 to 4.
  o    Disitamab vedotin. Chinese clinical trials from 21 to 24. 
  o    Tisotumab vedotin. US clinical trials from 3 to 4

​

June 2024 

• All links were checked and are working appropriately. 
  NOTE: Clinical trial numbers were updated and may include Phase 3, as well as Phase 2 and Phase 1 if ongoing.  
  o    Cytarabine: US clinical trials from 415 to 411, European clinical trials from 123 to 120
  o    Omega-3-acid ethyl ester/Lovaza: US active clinical trials rose from 18 to 21.  Europe active clinical trials for “Lovaza” yielded no change in active clinical trials, but a search for “omega-3-acid ethyl ester” yielded a change from none to 1. Japan active clinical trials dropped from 4 to 3.
  o    Omega-3-carboxylic acids/Epanova:  Japan active clinical trials for “Epanova” yielded a change from none to 1
  o    Eribulin Mesylate: US clinical trials from 73 to 79.   Europe active clinical trials dropped from 22 to 21. Chinese active clinical trials rose from 13 to 15 
  o     Brentuximab vedotin:  US active clinical trials dropped from 75 to 73. Chinese active clinical trials rose from 1 to 2 
  o    Trabectedin: US clinical trials from 21 to 22, European clinical trials from 21 to 20.
  o    Plitidepsin: US clinical trials from 1 to 0.
  o    Polatuzumab vedotin:  US clinical trials from 45 to 42, European clinical trials from 13 to 12, Japanese clinical trials from 5 to 6.
  o    Enfortumab vedotin-ejfv: US clinical trials from 32 to 34, Japanese clinical trials from 10 to 12 .
  o    Lurbinectedin: US clinical trials from 27 to 28.
  o    Disitamab vedotin. US clinical trials from 72 to 77, Chinese clinical trials from 19 to 21. 

​

May 2024 

• Jazz Pharmaceuticals (Ziconotide) sold rights to Prialt to TerSera Therapeutics, and the company has been updated. 

• Seagen was acquired by Pfizer, and the company and links (Brentuximab Vedotin, Enfortumab Vedotion, and Tisotumab Vedotin-tftv) have been updated. 

​

April 2024 

• All links were checked and working appropriately 

• Clinical trial numbers were updated accordingly

  •  Cytarabine: US clinical trials from 412 to 415, European clinical trials from 124 to 123

  •  Eicosapenta enoic acid ethyl ester: US clinical trials from 5 to 4 

  •  Eribulin Mesylate: US clinical trials from 72 to 73 

  • Brentuximab vedotin:  US clinical trials from 77 to 75 

  • Trabectedin: US clinical trials from 21 to 22, European clinical trials from 21 to 20

  • Polatuzumab vedotin: European clinical trials from 2 to 13, Chinese clinical trials from 1 to 2 

  • Enfortumab vedotin-ejfv: US clinical trials from 30 to 32 

  • Lurbinectedin: Japanese clinical trials from 2 to 3 

  • Disitamab vedotin: Chinese clinical trials from 18 to 19

​

March 2024 

• All links were checked and working appropriately 

• Clinical trial numbers were updated accordingly

  • Cytarabine US clinical trials from 415 to 412, European clinical trials from 125 to 124, Chinese clinical trials from 56 to 57 

  • Vidarabine US clinical trials from 21 to 23 

  • Omega-3-acid ethyl esters US clinical trials from 19 to 18, Japanese clinical trials from 3 to 4 

  • Eicosapenta enoic acid ethyl ester US clinical trials from 4 to 5 

  • Eribulin Mesylate US clinical trials from 67 to 72 

  • Brentuximab vedotin US clinical trials from 76 to 77 

  • Trabectedin US clinical trials from 20 to 21 

  • Polatuzumab vedotin Japanese clinical trials from 3 to 5 

  • Enfortumab vedotin-ejfv US clinical trials from 28 to 30 

  • Lurbinectedin US clinical trials from 28 to 27, Japanese clinical trials from 1 to 2 

  • Disitamab vedotin US clinical trials from 71 to 72, Chinese clinical trials from 15 to 18 

​

February 2024 

• All links were checked and working appropriately 

• Clinical trial numbers were updated accordingly​

  • Cytarabine US clinical trials from 411 to 415, Japanese clinical trials from 20 to 21, Chinese clinical trials from 55 to 56 

  • Eribulin Mesylate US clinical trials from 68 to 67 

  • Brentuximab vedotin US clinical trials from 77 to 76 

  • Trabectedin European clinical trials from 22 to 21 

  • Polatuzumab vedotin Japanese clinical trials from 4 to 3 

  • Enfortumab vedotin-ejfv US clinical trials from 30 to 28, European clinical trials from 10 to 9 

  • Lurbinectedin US clinical trials from 26 to 28 

  • Disitamab vedotin US clinical trials from 65 to 71, Chinese clinical trials from 14 to 15 

​

January 2024

• All links were checked and are working appropriately.

• Clinical trial numbers were updated accordingly.

  • Cytarabine US clinical trials from 422 to 411, Japanese clinical trials from 19 to 20 

  • Vidarabine US clinical trials from 24 to 21 

  • Omega-3-acid ethyl esters US clinical trials from 17 to 19, Japanese clinical trials from 0 to 3 

  • Eicosapenta enoic acid ethyl ester US clinical trials from 7 to 4 

  • Eribulin mesylate Japanese clinical trials from 7 to 6, Chinese clinical trials from 12 to 13 

  • Brentuximab vedotin US clinical trials from 75 to 77, Japanese clinical trials from 2 to 1 

  • Polatuzumab vedotin US clinical trials from 44 to 45, Japanese clinical trials from 3 to 4 

  • Lurbinectedin US clinical trials from 25 to 26 

  • Disitamab vedotin US clinical trials from 60 to 65, Japanese clinical trials from 0 to 1, Chinese clinical trials from 12 to 14 

  • Tisotumab vedotin-tftv US clinical trials from 4 to 3 

​

December 2023 ​ ​

• All links were checked and are working appropriately.

• Clinical trial numbers were updated accordingly.

  • Cytarabine US clinical trials from 420 to 422, Japanese clinical trials from 22 to 19, and Chinese clinical trials from 54 to 55

  • Vidarabine US clinical trials from 23 to 24

  • Eribulin mesylate Chinese clinical trials from 10 to 12

  • Brentuximab vedotin US clinical trials from 77 to 75

  • Trabectedin US clinical trials from 21 to 20

  •  Polatuzumab vedotin Chinese clinical trials from 0 to 1

  •  Enfortumab vedotin US clinical trials from 29 to 30 and Japanese clinical trials from 9 to 10

  • Lurbinectedin US clinical trials from 23 to 25

  • Disitamab vedotin US clincal trials from 56 to 60 and Chinese clinical trials from 11 to 12

​

October 2023 ​

• All links were checked and the Mochida Pharmaceutical link https://www.mochida.co.jp/english/business/mainproducts.html is intermittently giving an error that it "can’t provide a secure connection”. All other links are working as expected.

• Japanese clinical trials information is being added to the table. https://rctportal.niph.go.jp/en/result

• Clinical trial numbers were updated accordingly.

  • Cytarabine US clinical trials from 423 to 420, European clinical trials from 127 to 125, and Japanese clinical trials from 23 to 22

  • Brentuximab vedotin US clinical trials from 81 to 77, and European clinical trials from 40 to 39

  • Trabectedin US clinical trials from 20 to 21

  •  Polatuzumab vedotin US clinical trials from 40 to 44

  •  Enfortumab vedotin European clinical trials from 11 to 10

  • Disitamab vedotin US clincal trials from 51 to 56

​

September 2023 ​

• All links were checked and working properly.

• Japanese clinical trials information was checked as well.

• Clinical trial numbers were updated accordingly.

  • Cytarabine US clinical trials from 432 to 423, European clinical trials from 126 to 127, and Japanese clinical trials from 22 to 23

  • Vidarabine US clinical trials from 22 to 23, Japanese clinical trials 5

  • Omega-3-acid ethyl esters US clinical trials from 18 to 17 

  • Eicosapentaenoic acid ethyl esters Japanese clinical trials 2

  • Eribulin mesylate Japanese clinical trials 7 

  • Brentuximab vedotin US clinical trials from 82 to 81 and Japanese clinical trials 2

  • Polatuzumab vedotin US clinical trials from 39 to 40 and Japanese clinical trials 3

  • Enfortumab vedotin US clincal trials from 28 to 29 and Japanese clinical trials from 12 to 9

  • Lurbinectedin US clincal trials from 24 to 23 and Japanese clinical trials 1

  • Disitamab vedotin US clincal trials from 47 to 51 and Chinese clinical trials from 10 to 11

​

August 2023 ​

• All links were checked and working properly.

• Japanese clinical trials information was checked as well.

• Clinical trial numbers were updated accordingly.

  • Cytarabine US clinical trials from 434 to 432, European clinical trials from 127 to 126, and Japanese clinical trials 22

  • Vidarabine US clinical trials from 23 to 22 and Japanese clinical trials 5

  • Eicosapentaenoic acid ethyl esters Japanese clinical trials 2

  • Eribulin Mesylate US clinical trials from 66 to 68 and Japanese clinical trials 7 

  • Brentuximab vedotin US clinical trials from 84 to 82 and Japanese clinical trials 2 

  • Trabectedin US clinical trials from 21 to 20

  • Polatuzumab vedotin US clinical trials from 37 to 39 and Japanese clinical trials 3

  • Enfortumab vedotin US clincal trials from 28 to 29 and Japanese clinical trials 12

  • Lurbinectedin US clincal trials from 24 to 23 and Japanese clinical trials 1

  • Disitamab vedotin US clincal trials from 47 to 51 and Chinese clinical trials from 8 to 10

​

July 2023 ​

• All links were checked and working properly.

• Clinical trial numbers were updated accordingly.

  • Cytarabine US clinical trials from 440 to 434 and Chinese clinical trials from 53 to 54

  • Vidarabine US clinical trials from 24 to 23

  • Omega-3-acid ethyl esters US clinical trials from 20 to 18

  • Eicosapentaenoic acid ethyl ester US clinical trials from 4 to 7

  • Eribulin Mesylate US clinical trials from 33 to 66 and Chinese clinical trials from 9 to 10

  • Brentuximab vedotin US clinical trials from 71 to 84 

  • Trabectedin US clinical trials from 19 to 21

  • Polatuzumab vedotin US clinical trials from 25 to 37

  • Enfortumab vedotin US clinical trials from 21 to 28, European clinical trials from 10 to 11, and Chinese clinical trials from none to

  • Lurbinectedin US clinical trials from 23 to 24

  • Disitamab vedotin US clincal trials from 32 to 47 and Chinese clinical trials from 7 to 8

​